HealthDay News — For patients with moderate-to-severe plaque psoriasis, bimekizumab is noninferior and superior to secukinumab and adalimumab, according to 2 studies published in the New England Journal of Medicine to coincide with the American Academy of Dermatology VMX 2021 meeting, held virtually from April 23 to 25.
Kristian Reich, MD, PhD, from the University Medical Center Hamburg-Eppendorf in Germany, and colleagues randomly assigned patients with moderate-to-severe plaque psoriasis to receive either bimekizumab every 4 weeks (373 patients) or secukinumab (weekly to week 4, then every 4 weeks; 370 patients). At week 16, patients receiving bimekizumab were rerandomized to receive maintenance dosing every 4 weeks or every 8 weeks. The researchers found that 61.7% and 48.9% of patients in the bimekizumab and secukinumab groups, respectively, had a 100% reduction from baseline in the Psoriasis Area and Severity Index score (PASI 100; adjusted risk difference, 12.7 percentage points).
Richard B. Warren, MD, from the University of Manchester in the United Kingdom, and colleagues randomly assigned patients with moderate-to-severe plaque psoriasis to receive subcutaneous bimekizumab (320 mg every 4 weeks to 56 weeks; 158 patients), bimekizumab (320 mg every 4 weeks for 16 weeks, then every 8 weeks to 56 weeks; 161 patients), or subcutaneous adalimumab (40 mg every 2 weeks for 24 weeks) followed by bimekizumab (320 mg every 4 weeks to week 56; 159 patients). One of the primary endpoints was PASI 90 response. The researchers found that 86.2% of patients from both dose groups who received bimekizumab had a PASI 90 response compared with 47.2% of those receiving adalimumab (adjusted risk difference, 39.3%).
“Longer, larger trials are required to determine the efficacy and safety of bimekizumab for the treatment of psoriasis,” Warren and colleagues write.
Several authors from both studies disclosed financial ties to pharmaceutical companies, including UCB Pharma, which manufactures bimekizumab and funded both studies.